Echosens

21/10/2026

👏 That's a wrap on in Barcelona!

A big thank you to everyone who visited the Echosens booth and connected with our team throughout one of the leading congresses in gastroenterology.

It was a pleasure to exchange with healthcare professionals from around the world and discuss the growing role of non-invasive solutions in liver disease management.

See you at the next congress!

20/10/2026

🔎 What should clinicians consider when evaluating liver health management solutions?

A recent article from American Healthcare Leader offers an insightful perspective and highlights the value of FibroScan®.

“Best value represents a combination of clinical accuracy, device reliability, long-term vendor support and a clear return on investment. Look for vendors who are pioneers in the field with a proven track record and extensive clinical validation.”

➡️ The FibroScan® family of solutions combines expansive clinical evidence with a range of products designed to meet the needs of patients and physicians across specialties and care settings.

“True value comes from proven clinical accuracy backed by extensive peer-reviewed research, a clear return on investment from improved outcomes, and efficiency gains and strong vendor support that extends throughout the device’s lifetime.”

👏 Thank you, American Healthcare Leader, for recognizing what truly defines value in liver health management.

📰Read the full article: How Healthcare Leaders Can Evaluate High-Value Liver Health Management Solutions - American Healthcare Leader

Learn how healthcare leaders can evaluate liver health management solutions based on clinical accuracy, workflow efficiency, integration, adaptability and ROI.

19/10/2026

👋 Join Echosens, the makers of FibroScan®, at CVRM Professional Care 2026 for our sponsored symposium:

➡️ MASLD: a practical approach to diagnosis, staging and management Professor Stuart McPherson, Consultant Hepatologist, Newcastle

📅 20 October 2026 | 10:30–11:00 📍 Keynote Theatre, Olympia London

This session will discuss the burden of MASLD in clinical practice, the relationship between liver and cardiometabolic health, and practical approaches to identifying patients at risk of advanced fibrosis using simple non-invasive tests

Also visit us at Stand D25 to meet the team, explore our FibroScan® solutions and find out how we can support you in delivering better CVRM care

17/10/2026

We’re proud to announce a new strategic partnership with Gastro Health, one of the United States’ largest gastroenterology medical groups, to advance non-invasive liver assessment and metabolic disease management.

➡️ Through this collaboration, Gastro Health will integrate FibroScan® into its enterprise-wide approach to liver health care, helping physicians identify liver disease risk earlier, guide clinical decisions, and monitor patients over time.

🤝 We’re bringing to this partnership 25 years of leadership in non-invasive liver assessment, an extensive body of peer-reviewed evidence behind FibroScan®, and eagerness to help Gastro Health expand access to objective liver health information at the point of care.

📰 Read more about the partnership: Echosens and Gastro Health Partner to Advance Non-Invasive Liver Health Assessment and Metabolic Disease Management https://www.prnewswire.com/news-releases/echosens-and-gastro-health-partner-to-advance-non-invasive-liver-health-assessment-and-metabolic-disease-management-302908766.html?tc=eml_cleartime

/PRNewswire/ -- Echosens, the global leader in non-invasive liver assessment, today with Gastro Health, one of the nation's largest gastroenterology medical...

13/10/2026

That's a wrap for ACG 2026 in Nashville! 🎉

A sincere thank you to everyone who visited us. It was a pleasure sharing how FibroScan® is helping support earlier liver disease detection and better patient management

👋 Until next time!

12/10/2026

🎥 More than 1500 registrations for key topic shaping the future of liver health!

The response to our webinar "Baveno VIII in Practice" reflected the global interest in the latest recommendations for non-invasive risk stratification in portal hypertension.

Beyond attracting healthcare professionals from over 100 countries, the webinar fostered discussions on the implementation of the Baveno VIII Consensus. Through their expert insights, Prof.Juan Gonzalez Abraldes and Dr.Elton Dajti explored the role of NITs and FibroScan®-based biomarkers in the updated guidelines, while the high level of audience engagement highlighted a clear demand for practical guidance in clinical practice.

If you missed it, here are the 4 key takeaways:
🔹 A unified CSPH framework across all aetiologies — ANTICIPATE-NASH and NICER models provide individualised risk estimates, with a single ≥75% rule-in threshold regardless of aetiology.

🔹 Spleen stiffness (100 Hz) is now formally validated — SSM >55 kPa rules in CSPH; SSM

09/10/2026

📍 C'est déjà le dernier jour de l'AFEF 2026 !

Quelle semaine à Strasbourg ! Merci à tous ceux qui sont venus rencontrer les équipes Echosens et découvrir comment les solutions non invasives contribuent à transformer la prise en charge des maladies du foie.

Au programme de ces derniers jours :
✅ Démonstrations en direct du FibroScan® sur le foie et la rate sur notre stand
✅ Échanges autour des dernières avancées en hépatologie et des parcours de soins non invasifs
✅ Workshop dédié aux nouvelles recommandations Baveno VIII sur la prise en charge des patients atteints de maladie chronique du foie avancée, animé par le Pr. Dominique Thabut et le Pr. Pierre-Emmanuel Rautou, qui a réuni près de 100 participants

Vous êtes à l'AFEF aujourd'hui ? Il est encore temps de passer nous voir !

08/10/2026

📍 Join Echosens at booth #406 during the ACG Annual Scientific Meeting, taking place in Nashville from October 9-14

➡️ Discover how FibroScan® is helping gastroenterologists advance liver disease assessment through a fast, non-invasive approach, supporting earlier detection and better patient management.

👋Come and meet our team to discuss about our contribution to the liver care

We look forward to seeing you in Nashville!

05/10/2026

ℹ️ Pediatric MASLD is more than adult MASLD showing up earlier.

Children and adolescents bring a different clinical reality: Their bodies are still growing, their metabolic risk is shaped by development, and the way their progress is assessed must reflect that.

📃 In her white paper, Dr. Alisha Mavis explains why recognizing those differences is essential to evaluating risk and caring for children more thoughtfully. https://www.echosens.com/en-us/wp-mavis/

29/09/2026

📸 The Echosens team is live at 2026!

We're proud to be in Milan until October 2, joining the global diabetes and metabolic health community for a week of scientific exchange, innovation and collaboration.

➡️ Stop by booth H.07 to meet our team and learn how FibroScan® is helping healthcare professionals integrate non-invasive liver assessment into the management of metabolic diseases.

👋 Hope to see you soon!